MicroRNA-23a: A Novel Serum Based Diagnostic Biomarker for Lung Adenocarcinoma

• Published in: Tuberculosis and respiratory diseases Vol. 71; no. 1; pp. 8 - 14
• Main Authors: Lee, Yu Mi, Cho, Hyun-Jung, Lee, Soo Young, Yun, Seong Cheol, Kim, Ji Hye, Lee, Shin Yup, Kwon, Sun Jung, Choi, Eugene, Kang, Jae-Ku, Son, Ji Woong
• Format: Journal Article
• Language: English
• Published: 대한결핵및호흡기학회 01.07.2011
• Subjects: 내과학
• ISSN: 1738-3536; 2005-6184
• DOI: 10.4046/trd.2011.71.1.8

Background: MicroRNAs (miRNAs) have demonstrated their potential as biomarkers for lung cancer diagnosis. In recent years, miRNAs have been found in body fluids such as serum, plasma, urine and saliva. Circulating miRNAs are highly stable and resistant to RNase activity along with, extreme pH and temperatures in serum and plasma. In this study, we investigated serum miRNA profiles that can be used as a diagnostic biomarker of non-small cell lung cancer (NSCLC). Methods: We compared the expression profile of miRNAs in the plasma of patients diagnosed with lung cancer using an miRNA microarray. The data from this assay were validated by quantitative real-time PCR (qRT-PCR). Results: Six miRNAs were overexpressed and three miRNAs were underexpressed in both tissue and serum from squamous cell carcinoma (SCC) patients. Sixteen miRNAs were overexpressed and twenty two miRNAs were underexpressed in both tissue and serum from adenocarcinoma (AC) patients. Of the four miRNAs chosen for qRT-PCR analysis, the expression of miR-23a was consistent with microarray results from AC patients. Receiver operating characteristic (ROC) curve analyses were done and revealed that the level of serum miR-23a was a potential marker for discriminating AC patients from chronic obstructive pulmonary disease (COPD) patients. Conclusion: Although a small number of patients were examined, the results from our study suggest that serum miR-23a can be used in the diagnosis of AC. KCI Citation Count: 0